A recent study (AS Elnaggar et al. Liver Transplantation 2018; 24: 881-87; editorial 868-9) examine the effect of different types of surgical shunts in the setting of portal vein thrombosis (PVT). The authors examined surgical shunts from 1998-2011 in their institution (senior author: Jean Emond).
- 40 patients received “portal flow-preserving shunts”: 32 mesoportal and 8 selective splenorenal
- 24 received portal flow-diverting shunts (16 nonselective splenorenal and 8 mesocaval)
- Of these 64 patients, only 39 had preoperative and postoperative cross-sectional imaging. In addition, only 11 patients who had mesoportal shunt (7 children and 4 adults) had preoperative and postoperative cross-sectional imaging allowing for volume comparison.
- In patients receiving portal flow-preserving shunts (mainly mesoportal), this was associated with liver volume expansion (886 versus 1131 cm to the third), whereas diverting shunts were not.
The authors note that liver atrophy, especially in children, can have a “significant effect on cognitive function and somatic growth.” Thus, restoring portal flow may improve adverse effects that PVT has caused.
- Lack of validation of their formula to calculate liver volumes in the pediatric age group
- Relatively short follow-up:5.7 months in the portal-preserving group and 11 months in the other group
- Small numbers of patients..
Long-term followup of patients who have needed surgical shunts is needed. For mesoportal shunts, strictures have been noted in the hepatic end in 15% of patients.
My take: This study shows that portal blood flow, which was interrupted by PVT and restored by mesoportal (Rex) shunt, is important in maintaining liver mass. So, while all shunts may stop upper GI bleeding, mesoportal shunt is likely to improve other adverse effects of PVT.
Virginia Museum of Fine Arts (Richmond) has acquired Chihuly’s Red Reeds
Background: Transient elastography may help identify patients at greater risk for advanced fibrosis but there is a significant overlap between fibrosis stages and values with transient elastography. In some conditions, like fatty liver, elastography may be less helpful than in others (eg. chronic viral hepatitis).
A recent study (J Pediatr 2018; 198: 84-9) examined the results of transient elastography in 267 children (97 for calibration, 170 for validation) between 2006-2016. The median age was 13 years. Liver diseases included autoimmune (21%), viral (19%), fatty liver (11%), cholestatic (9%), primary sclerosing cholangitis (9%) and post-transplantation (12%).
- Cut points to discriminate F3-F4 and F4 were >8.6 kPa and >11.5 with 81% and 84% accuracy, respectively in calibration cohort
- To discriminate F3-F4 and F4 in validation cohort, these cut points, >8.6 kPa and >11.5, had accuracy of 67% and 75% respectively
Figure 2 provides much greater detail in the typical values for each Metavir stage. For example, in the calibration cohort, the median values and range were the following:
- F0 6.0 (3.2-12.4)
- F1 6.2 (3.2-75)
- F2 5.8 (2.5-52.7)
- F3 10.3 (4.9-32.6)
- F4 20.5 (5.9-68.1)
In the validation cohort, values were similar:
- F0 6.2 (3.0-75.0)
- F1 7.1 (3.3-31.6)
- F2 7.1 (2.5-52.7)
- F3 9.6 (4.4-75.0)
- F4 20.8 (6.8-75.0)
My take: Elastography in measuring liver stiffness is a lot like checking a CRP for inflammatory bowel disease. That is, it can be helpful but cannot be relied on the same way as many radiographic tests (eg. CT scans for appendicitis).
Related blog post:
Moraine Lake, Banff
It is recognized that there is often a delay in the diagnosis of biliary atresia (BA). A recent study (MR Townsend et al. J Pediatr 2018; 199: 237-42) indicates that hepatoportoenterostomy (HPE) or Kasai procedure is performed in only 37.7% of patients with BA prior to 60 days of age. The data was obtained from the Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample files from 2000-2011.
- Risk factors for delayed HPE: This study of 1243 patients with BA found that those with delayed HPE were more often uninsured–all self-pay patients had HPE after 60 days, more often black (aOR 4.22), and less likely at a teaching hospital (aOR 0.27).
- Delayed HPE was associated with increased adverse perioperative outcomes and increased cost.
My take: We have a long way to go if we are going to consistently identify and treat BA in a timely manner.
Related blog posts:
A recent study (P Kumar et al. JPGN 2018; 67: 75-9) examined suspected NAFLD in 12 to 18 year olds using data from NHANES. In the analysed cohort, there were 124 suspected NAFLD and 1385 without suspicion of NAFLD. This subset was weight to represent a U.S. population of over 18 million.
- Suspected NAFLD was defined by abnormal ALT (>25.8 U/L for boys and >22.1 U/L for girls) who did not have another explanation (eg. viral hepatitis, medication)
- Lean BMI was defined by BMI less than 85th% for age
- Hypertriglyceridemia ≥ 150
- Low HDL ≤ 40 mg/dL
- HOMA-IR =fasting glucose x insulin (microU/mL) divided by 405. Insulin resistance was defined as HOMA-IR ≥ 3
- Suspected NAFLD affects ~8% of lean adolescents in the U.S.
- Hypertriglyceridemia was noted in 10 of 124 suspected NAFLD and was a risk factor (P=0.028) as was Low HDL which occurred in 15 (P=0.016) and IR which occurred in 43 (P=0.053)
My take: Elevated ALT, a marker for fatty liver disease, is common even in adolescents without obesity. Elevated triglycerides, low HDL, and insulin resistance are all risk factors for suspected NAFLD in non-overweight/non-obese teens.
Related blog posts:
Cumberland Island 2018
Briefly noted: A small pilot study (n=9) (SS Sundaram et al. J Pediatr 2018; 198: 67-75) showed that treatment (with home CPAP) of obstructive sleep apnea (OSA) was associated with improved alanine aminotransferase levels, reduced metabolic syndrome markers and lower F(2)-isoprostanes (a marker of oxidative stress) in pediatric patients with nonalcoholic fatty liver disease (NAFLD). All nine of the participants were Hispanic males with a median age of 11.5 years; they had a median BMI of 29.5 and had biopsy-proven NAFLD. The improvement in NAFLD parameters occurred despite an increase in BMI. The authors note that studies in adults have shown contradictory findings with regard to whether treatment of OSA helps NAFLD.
My take: This study suggests potential beneficial liver effects of treating OSA. Regardless, treatment of OSA could be considered a quality metric in the care of children with NAFLD as better sleep at night has additional clear benefits.
Related blog posts:
Outside Mercedes-Benz Stadium (Atlanta)
An important metric of liver transplantation outcome is not readily available: acceptance of organ offers. A recent study (E Mitchell et al. Liver Transplantation 2018; 24: 803-809) showed a great deal of variability among pediatric liver transplantation centers in this metric.
The authors examined data from 2007-2015 with 4088 unique patients and 27,094 match runs. The range in organ acceptance rates was 5.1% to 14.6% with a median of 8.9%.
- “Center-level acceptance rates were associated with wait-list mortality, with a >10% increase in the risk of wait-list mortality for every 1% decrease in a centers adjusted liver offer acceptance rate (odds ratio, 1.10, CI 1.01-1.19)
As noted in a previous post, Pediatric Liver Transplantation -Past Time to Split, larger centers generally have higher acceptance rates.
My take: This study adds to the literature regarding the inequities that some patients unknowingly face when listed in some centers.
Related article: HPJ van der Doef et al. Liver Transplantation 2018; 24: 810-9. This article describes the wait-list mortality of young patients with biliary atresia. Those listed before age 6 months and with higher MELD scores (>20) were at increased risk. Recognition of these factors may help improve allocation.
Related blog posts:
Hate it when this happens!
A recent study (S Harpavat et al. JPGN 2018; 66: 850-6) identifies race/ethnicity as a factor affecting the timeliness of diagnosis.
Specifically, non-Hispanic white infants were diagnosed earlier than non-Hispanic black infants and Hispanic infants (P=.007); this was related to the timing of referral from the primary care physician. The authors speculate that this could be related to three factors:
- lighter colored skin could help identify jaundice more quickly
- better access to health care
- implicit bias leading to uneven treatment
The other finding in the study was that after referral, patients referred after 30 days of life had a more expedited diagnosis than those referred prior to 30 days of life. The authors caution that the histology in these early cases is similar to those who present later, even if their aminotransferases are normal. In addition, while physicians and parents want to avoid ‘over testing,’ prompt diagnosis, even prior to 30 days of life, may lead to improved outcomes. Thus, the authors recommend proceeding with liver biopsy if there is clinical suspicion of biliary atresia.
My take: Obtaining objective evidence of cholestasis in infants that are jaundiced beyond 2 weeks of life is important. This study highlights some of the reasons why the diagnosis is delayed in so many.
Related blog posts: